Gastric Electrical Stimulation (GES) and Pyloroplasty for the Treatment of Gastroparesis
NCT03123809 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2025-05-15
Summary
Gastroparesis (GP) is describing a condition when stomach does not empty as fast as it should. This fact creates the situation, when food stays in the stomach for a long time and it causes symptoms of nausea, vomiting, loss of appetite, bloating, inability to finish normal size meal and abdominal pain. There are not many drugs available to treat this condition and majority of gastroparetic patients are not responding well to them after they are on it for some time. Many investigators are able to implant Gastric Stimulator System (GES) under FDA approved status of Humanitarian Device Exemption (HDE) definition. In the last few years it became possible to add another surgical procedure, which is called pyloroplasty (making bigger opening on the end of stomach), may help even more as it is also increasing the rate of the emptying of the stomach. Therefore this study is proposing to evaluate if GES in combination with pyloroplasty is much better than pyloroplasty alone. For this reason, two of these procedures will be introduced surgically at the same time, but GES devices will not be turn ON in half of these participants for 3 months. After that time all subjects will have their devices turned ON. All subjects will be asked to evaluate their symptoms of gastroparesis and their quality of life during clinical visits, and investigators will conduct pathological analyses of tissue obtained during surgery.
Conditions
Interventions
- DEVICE
-
Gastric Electrical Stimulation (GES) System
Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.
Sponsors & Collaborators
-
Texas Tech University Health Sciences Center, El Paso
lead OTHER
Principal Investigators
-
Irene Sarosiek, MD · Texas Tech University Health Sciences Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-10
- Primary Completion
- 2023-09-15
- Completion
- 2024-10-30
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)
NCT00157755 ·Status: TERMINATED ·Phase: NA
-
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
NCT06560307 ·Status: RECRUITING ·Phase: NA
-
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis
NCT00612014 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Blenderized Enteral Tube Feeds on Pediatric Upper Gastrointestinal Tract Physiology
NCT04900597 ·Status: RECRUITING ·Phase: NA
-
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
NCT01664637 ·Status: TERMINATED ·Phase: PHASE2
-
Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study
NCT04706832 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Thoracic Neuromodulation for Diabetic Gastroparesis
NCT05273788 ·Status: RECRUITING ·Phase: PHASE1
-
Outcome Study of Endoscopically Inserted Gastrostomy (PEG)Versus Radiologically-guided Insertion of Gastrostomy (RIG)in Children
NCT01920438 ·Status: UNKNOWN ·Phase: NA
-
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
NCT01571297 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Tolerance and Safety of Early Enteral Nutrition in Children After Percutaneous Endoscopic Gastrostomy Placement
NCT02777541 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
NCT04303195 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis
NCT00639808 ·Status: COMPLETED ·Phase: PHASE1
-
Enterra Therapy Gastric Stimulation System
NCT00556166 ·Status: TERMINATED ·Phase: PHASE4
-
Feasibility of Aerodigestive Stimulation Therapy Trial
NCT06118697 ·Status: RECRUITING ·Phase: NA
-
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
NCT04028492 ·Status: COMPLETED ·Phase: PHASE3
-
Intraumbilical Amino Acids and Glucose Supplementation Via Port by Severe IUGR in Human Fetuses
NCT02596594 ·Status: COMPLETED ·Phase: NA
-
Enteral Glutamine Supplementation for the Patient With Major Torso Trauma
NCT00178581 ·Status: TERMINATED ·Phase: PHASE1
-
PES to Avoid Extubation Failure in Intubated Stroke Patients at High Risk of Severe Dysphagia
NCT04010617 ·Status: UNKNOWN ·Phase: NA
-
Elemental Diets vs. Semi-solid Diets on Gastric Excretion and Gastroesophageal Regurgitation
NCT02290626 ·Status: WITHDRAWN ·Phase: NA
-
Short Bowel Syndrome and Teduglutide Versus Placebo
NCT02099084 ·Status: COMPLETED ·Phase: PHASE4
-
Trial- Dysphagia From ETT or GI Endoscopy
NCT02460055 ·Status: WITHDRAWN ·Phase: NA
-
Feasibility Study to Evaluate Safety of Nutriseal™ Nutriplace™ System
NCT03371160 ·Status: TERMINATED ·Phase: NA
-
Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends
NCT07341464 ·Status: RECRUITING ·Phase: NA
-
Optimal Feeding Tube Placement
NCT04241146 ·Status: COMPLETED ·Phase: NA
-
Steroid Versus Mitomycin-C Use in Pediatric Benign Recurrent Esophageal Stricture
NCT06626802 ·Status: COMPLETED ·Phase: NA